La FDA ha ampliado el plazo hasta que la compañia aporte una nueva información, porque Hemispherx ha explicado a la FDA que parecen haber descubierto un posible test diagnóstico para el SFC.
Por lo visto, comparando secuencias de ADN entre los enfermos de SFC y controles sanos del estudio de Ampligen, han encontrado diferencias estadísticas significativas entre ambos grupos, por lo que las pruebas del Ampligen parecen haber llevado al descubrimiento de este posible test diagnóstico para el Síndrome de Fatiga Crónica.
(esto no es una traducción literal, me ha costado un huef (por no decir un egg

[t]FDA grants NDA extension for Hemispherx CFS therapeutic[/t]
Published 12 January 2012
The US Food and Drug Administration (FDA) has granted an extension for the Hemispherx Biopharma to modify its new drug application (NDA) for the Chronic Fatigue Syndrome (CFS) therapeutic indication.
The extension will remain open while Hemispherx submits an amended NDA, the company said.
In the request for extension, the company advised the FDA of the findings of a new potential companion diagnostic test for CFS.
The proof of principle study compared sequences from massively parallel sequenced serum DNA (Deoxyribonucleic Acid) extracted from either well vetted Hemispherx CFS sera or matching controls.
Signature DNA sequences were identified that showed statistically significant separation of CFS serum from matching control serum.
Hemispherx medical director David Strayer said they are working diligently to pursue approval for Ampligen as the first treatment for Chronic Fatigue Syndrome in the US and other countries.
enlace: http://regulatoryaffairs.pharmaceutical ... tic-120112" onclick="window.open(this.href);return false;